Clinical trial NCT03884777: Incidence and Risk of Influenza in Myasthenic Patients
Official title: Incidence and Risk of Influenza in Myasthenic Patients Hospitalized in Intensive Care
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myasthenic Crisis
Upper Respiratory Infection
Keywords: Influenza A virus
myasthenia gravis
neurocritical care clinical
neuromuscular disease
Lead sponsor: Centre d'Investigation Clinique et Technologique 805
Sponsor class: OTHER
First posted: 2019-03-21
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inclusion of 416 cases of myasthenic patients treated in the intensive care unit of Garches Hospital between January 1, 2009 and December 31, 2017.

Brief summary: Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases, can precipitate a myasthenic crisis

In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.

Detailed description: This is a descriptive study. The data will be analyzed retrospectively . Inclusion of 416 cases of influenza in myasthenic patients treated in the intensive care unit of Garches Hospital between January 1, 2009 and December 31, 2017.

Patients who meet the inclusion and non inclusion criteria and do not object to participate in the study will be collected in a database for analysis.

Eligibility criteria: Inclusion Criteria:

* Men or women over the age of 18.
* Myasthenic patients hospitalized in intensive care.
* Patients with confirmed influenza infection

Exclusion Criteria:

* Age \<18 years,
* Other neuromuscular diseases,
* Patient opposing the use of his data

Primary outcomes:
measure: Incidence of influenza in myasthenic patient in crisis
timeFrame: between January 1, 2009 and December 31, 2017.
Secondary outcomes:
measure: Risk factors for poor outcomes
timeFrame: between January 1, 2009 and December 31, 2017.
Other outcomes:
Locations:
Study officials:
affiliation: Raymond Poincaré Hospital
name: Rania BOUNAB, Dr
role: STUDY_DIRECTOR
References:
citation: Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):60. doi: 10.1038/nrmicro.2017.146. Epub 2017 Nov 7.
citation: Tackenberg B, Schneider M, Blaes F, Eienbroker C, Schade-Brittinger C, Wellek A, Deschauer M, Eickmann M, Klenk HD, Muller HH, Sommer N. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). EBioMedicine. 2018 Feb;28:143-150. doi: 10.1016/j.ebiom.2018.01.007. Epub 2018 Jan 10.
citation: Friman G, Schiller HH, Schwartz M. Distubed neuromuscular transmission in viral infections. Scand J Infect Dis. 1977;9(2):99-103. doi: 10.3109/inf.1977.9.issue-2.08.
citation: Rosciszewska D, Bluszcz M, Kurek H. [Antibodies for DNA and RNA viruses in the serum of myasthenia patients. Preliminary report]. Neurol Neurochir Pol. 1981 Sep-Dec;15(5-6):541-4. Polish.